CTRP9 treatment significantly decreases matrix metalloproteinase2/matrix metalloproteinase 9 (MMP2/MMP9) activity and TGF-β1 production, the two most significant mechanisms contributing to post-MI fibrosis [73]. The gene discussed is MMP9; the disease is myocardial infarction.